The case and the decision

The synthetic case combines compensated haemolysis, dehydrated red cells, iron overload and a potassium rise after blood is left unseparated. A Gardos-channel blocker reduces potassium loss from washed cells. Neither channel gene has been sequenced.

Where MontMedical gives the stronger account

OpenEvidence correctly names the broad PIEZO1-or-KCNN4 channelopathy in its opening. Later, its description of the blocker result moves towards DHS type 2, the KCNN4-associated subtype.

MontMedical explicitly explains the alternative: the Gardos potassium channel may be the primary defect, or it may be activated downstream of calcium entry through abnormal PIEZO1. Blocking the common downstream route can improve either mechanism.

The experiment that makes this concrete

This is more than a theoretical objection. Rapetti-Mauss and colleagues studied PIEZO1-mutant cells without a detected KCNN4 mutation. KCNN4 inhibitors reduced excess potassium loss and prevented dehydration. The response therefore supports Gardos-pathway involvement without uniquely identifying a KCNN4 mutation. [1]

The relevant next question is which gene is altered, addressed by suitable molecular testing and interpretation alongside the cell phenotype.

What OpenEvidence gets right

Its explanation of the red-cell cation leak is clear, and it brings the proposed splenectomy into focus early. Both answers recognise the disease pattern. The narrower MontMedical advantage is avoiding an unsupported subtype assignment; this example does not compare surgical outcomes or establish a product-wide diagnostic win.